Background: Kidney disease has been identified as a risk factor for vitamin D deficiency in hospitalized patients, and low levels of 25-hydroxyvitamin D have been suggested to be a risk factor for hyperparathyroidism in patients with chronic kidney disease (CKD). However, little is known about the magnitude of vitamin D deficiency in patients with CKD living in the United States. Methods: In this regard, we examined the levels of 25(OH)D in 43 patients with CKD and serum creatinine between 1 and 5 mg/dl (calculated glomerular filtration rate 111–11 ml/min per 1.73 m2) as well as in 103 patients undergoing hemodialysis. Results: In the predialysis patients, we found that 37 of the 43 patients (86%) had suboptimal levels of vitamin D (<30 ng/ml). Regression analysis indicated that there was a negative correlation between 25(OH)D and intact parathyroid hormone (PTH). Alkaline phosphatase showed a similar but less sensitive relationship. Serum albumin levels correlated with 25(OH)D levels. In contrast to findings reported in normal individuals, the levels of calcitriol correlated with those of 25(OH)D in the patients with CKD. In the group undergoing maintenance hemodialyis, we found that 97% of the patients had vitamin D levels in the suboptimal range, and there was no correlation of 25(OH)D levels with either PTH or serum albumin values. These data indicate that vitamin D insufficiency and deficiency are highly prevalent in patients with CKD and may play a role in the development of hyperparathyroidism. The functional significance of low levels of 25(OH)D in patients with stage 5 CKD remains to be determined.

Keywords:
Vitamin D, Chronic kidney disease, End-stage renal disease
1.
Martin KJ, Gonzalez EA, Slatopolsky E: Renal osteodystrophy; in Brenner BM, Rector FC (eds): The Kidney. Philadelphia, Saunders, 2004, pp 2255–2304.
2.
Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ: Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997;7:439–443.
3.
Tangpricha V, Pearce EN, Chen TC, Holick MF: Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002;112:659–662.
4.
Van der Wielen RP, Lowik MR, van den Berg H, de Groot LC, Haller J, Moreiras O, van Staveren WA: Serum vitamin D concentrations among elderly people in Europe. Lancet 1995;346:207–210.
5.
Dawson-Hughes B, Harris SS, Dallal GE: Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 1997;65:67–71.
6.
Passeri G, Pini G, Troiano L, Vescovini R, Sansoni P, Passeri M, Gueresi P, Delsignore R, Pedrazzoni M, Franceschi C: Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab 2003;88:5109–5115.
7.
Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS: Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777–783.
8.
Cannata-Andia JB, Gomez Alonso C: Vitamin D deficiency: A neglected aspect of disturbed calcium metabolism in renal failure. Nephrol Dial Transplant 2002;17:1875–1878.
9.
Fournier A, Fardellone P, Achard JM, Ghazali A, Pruna A, El Esper N, Moriniere P: Importance of vitamin D repletion in uraemia. Nephrol Dial Transplant 1999;14:819–823.
10.
Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:1–201.
11.
Docio S, Riancho JA, Perez A, Olmos JM, Amado JA, Gonzalez-Macias J: Seasonal deficiency of vitamin D in children: A potential target for osteoporosis-preventing strategies? J Bone Miner Res 1998;13:544–548.
12.
Papapoulos SE, Clemens TL, Fraher LJ, Gleed J, O’Riordan JL: Metabolites of vitamin D in human vitamin-D deficiency: Effect of vitamin D3 or 1,25-dihydroxycholecalciferol. Lancet 1980;ii:612–615.
13.
Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H: Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999;55:1019–1027.
14.
Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A: Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 1999;55:2169–2177.
15.
Halloran BP, Schaefer P, Lifschitz M, Levens M, Goldsmith RS: Plasma vitamin D metabolite concentrations in chronic renal failure: Effect of oral administration of 25-hydroxyvitamin D3. J Clin Endocrinol Metab 1984;59:1063–1069.
16.
Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E: Extra-renal production of calcitriol in chronic renal failure. Kidney Int 1988;34:368–375.
17.
Reichel H, Deibert B, Schmidt-Gayk H, Ritz E: Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 1991;6:162–169.
18.
Messa P, Vallone C, Mioni G, Geatti O, Turrin D, Passoni N, Cruciatti A: Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. Kidney Int 1994;46:1713–1720.
19.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
20.
Bayard F, Bec P, Ton That H, Louvet JP: Plasma 25-hydroxycholecalciferol in chronic renal failure. Eur J Clin Invest 1973;3:447–450.
21.
Saha H: Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol 1994;41:290–296.
22.
Hollis BW, Jacob AI, Sallman A, Santiz Z, Lambert PW: Circulating vitamin D and its photoproduction in uremia; in Norman AW, et al (eds): Vitamin D: Chemical, Biochemical and Clinical Endocrinology of Calcium Metabolism. Berlin, de Gruyter, 1982, pp 1157–1161.
23.
Holick MF: Vitamin D and the kidney. Kidney Int 1987;32:912–929.
24.
Loomis WF: Skin-pigment regulation of vitamin-D biosynthesis in man. Science 1967;157:501–506.
25.
MacLaughlin J, Holick MF: Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985;76:1536–1538.
26.
Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI, Willnow TE: An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999;96:507–515.
27.
Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637–1642.
28.
Lips P, Duong T, Oleksik A, Black D, Cummings S, Cox D, Nickelsen T: A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001;86:1212–1221.
29.
Dhesi JK, Bearne LM, Moniz C, Hurley MV, Jackson SH, Swift CG, Allain TJ: Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J Bone Miner Res 2002;17:891–897.
30.
Visser M, Deeg DJ, Lips P: Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003;88:5766–5772.
31.
Plotnikoff GA, Quigley JM: Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003;78:1463–1470.
32.
Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF: Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998;7:391–395.
33.
Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M: Extrarenal expression of 25-hydroxyvitamin D3–1 alpha-hydroxylase. J Clin Endocrinol Metab 2001;86:888–894.
34.
Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby MD, Moss PA, Chakraverty R: Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 2003;170:5382–5390.
35.
Moe SM, Hellman RN, Karp SL, Kraus M, Graves K, Li Q: Prevalence of calcidiol (25(OH)D2) insufficiency and deficiency and relationship to hyperparathyroidism by cross-sectional analysis in a geographically diverse stage 3 and 4 CKD patient population (abstract). J Am Soc Nephrol 2003;14:199A.
36.
Fournier A, Bordier P, Gueris J, Sebert JL, Marie P, Ferriere C, Bedrossian J, DeLuca HF: Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: Greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int 1979;15:196–204.
37.
Fournier A, Idrissi A, Sebert JL, Gueris J, Garabedian M, Renaud H, Westeel PF: Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3. Kidney Int Suppl 1988;24:S178–S179.
38.
Eastwood JB, Stamp TC, De Wardener HE, Bordier PJ, Arnaud CD: The effect of 25-hydroxy vitamin D3 in the osteomalacia of chronic renal failure. Clin Sci Mol Med 1977;52:499–508.
39.
Vieth R: Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69:842–856.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.